This site provides INTERCEPT product information for International audiences Select your region
Transfusion-related adverse events can be reduced when using INTERCEPT™ platelets thanks to two key mechanisms. First, the storage of platelets in platelet additive solutions (InterSol ,SSP+, T-PAS+, and PAS-IIIM) reduces the amount of plasma that can cause allergic reactions. Second, leukocytes are inactivated by the photochemical treatment of INTERCEPT with observed reduction in the production of a number of cytokines involved in inflammatory processes (Hei D, et al. Transfusion. 1999;39:239–48).